These findings indicate that ADRB2 has the potential to regulate the MAPK signaling pathway, suggesting that in CFs, ADRB2 may promote AP-1 transcription factor activity by activating the JNK/c-Jun pathway, thereby regulating IL-6 production. The gene discussed is ADRB2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.